Potential first-in-class

Discover the landscape of Potential first-in-class in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and intelligence on Potential first-in-class, helping you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli
CompanyDrug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

The US Food and Drug Administration (FDA) announced that it has approved AbbVie's (NYSE: ABBV) tavapadon for the treatment of Parkinson's disease, under the brand name Juvmo. Regulatory Milestone ItemDetailAgencyUS…

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Biokin's BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Biokin’s BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Biogen's Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus
CompanyDeals

Biogen’s Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus

Biokin's iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC
CompanyDrug

Biokin’s iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC

Servier’s Vorasidenib Enters China’s SPARK Program – First Dual IDH Inhibitor for IDH‑Mutant Glioma
CompanyDrug

Servier’s Vorasidenib Enters China’s SPARK Program – First Dual IDH Inhibitor for IDH‑Mutant Glioma

GSK Secures Worldwide Exclusive Rights to Empirico’s EMP‑012, a First‑in‑Class siRNA for COPD
CompanyDeals

GSK Secures Worldwide Exclusive Rights to Empirico’s EMP‑012, a First‑in‑Class siRNA for COPD

Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First‑In‑Class Glucokinase Activator
CompanyDrug

Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First‑In‑Class Glucokinase Activator

FibroGen Launches Phase 2 Dose‑Optimization Trial for CD46‑Targeted ADC FG‑3246 in Metastatic Castration‑Resistant Prostate Cancer
CompanyDrug

FibroGen Launches Phase 2 Dose‑Optimization Trial for CD46‑Targeted ADC FG‑3246 in Metastatic Castration‑Resistant Prostate Cancer

Hisun Pharma Secures China Rights to Ascentawits’ First‑In‑Class Drug AST‑3424
CompanyDeals

Hisun Pharma Secures China Rights to Ascentawits’ First‑In‑Class Drug AST‑3424

BeOne Secures $950 M Deal with Royalty Pharma for Tarlatamab Rights
CompanyDeals

BeOne Secures $950 M Deal with Royalty Pharma for Tarlatamab Rights

Show More